Part 4 Β· Chapter 4.3
Smooth Muscle
Smooth muscle is non-striated, involuntarily controlled, and operates under fundamentally different regulation from striated muscle: contraction is activated via myosin-light-chain kinase (MLCK) phosphorylation rather than troponin-C Ca2+ binding. This chapter covers MLCK/MLCP dynamics, Ca2+sensitisation via Rho kinase, and visceral smooth-muscle function.
1. MLCK Pathway
Cytosolic Ca2+ binds calmodulin (CaM); Ca2+4-CaM activates myosin-light-chain kinase (MLCK); MLCK phosphorylates Ser19 of the regulatory myosin light chain (MLC); phosphorylated myosin cycles cross-bridges on actin:
\[ \text{Ca}^{2+} \to \text{CaM} \to \text{MLCK} \to \text{pMLC}_{\text{Ser19}} \to \text{contraction} \]
Myosin-light-chain phosphatase (MLCP) dephosphorylates pMLC and relaxes the muscle. The force is set by the MLCK/MLCP ratio, not by Ca2+ alone.
2. Ca2+ Sensitisation
Rho kinase (ROCK) phosphorylates MYPT1 (MLCP regulatory subunit), inhibiting MLCP. This shifts the MLCK/MLCP balance toward phosphorylation, producing force at lower Ca2+ β so-called Ca2+ sensitisation. Gq (via RhoGEF) and G12/13 activate Rho. Fasudil and Y-27632 are Rho-kinase inhibitors; sildenafil indirectly opposes this via cGMP.
Simulation: Ca-MLCK-Force Coupling
Click Run to execute the Python code
Code will be executed with Python 3 on the server
3. Contractile Apparatus
Smooth-muscle thin filaments anchor to cytoplasmic dense bodies (Ξ±-actinin) and membrane dense plaques rather than Z-discs. Myosin II filaments are shorter and irregularly-oriented. The absence of striation reflects this lack of sarcomeric organisation. The consequence: slower but more economic contraction, ~1% of skeletal ATP consumption for the same tension, and a much wider operating length range.
4. Phasic vs Tonic Smooth Muscle
Phasic smooth muscle (GI, ureter, oviduct) produces rhythmic contractions coordinated by slow-wave-generating interstitial cells of Cajal (ICC). Tonic smooth muscle (vascular, airway) maintains sustained tone. Asthma, hypertension, and IBS all reflect smooth-muscle dysregulation; therapeutic targets include Ξ²2 agonists (albuterol, salbutamol), L-type Ca2+channel blockers (amlodipine, nifedipine), and guanylyl-cyclase stimulators.
Key References
β’ Somlyo, A. P. & Somlyo, A. V. (2003). βCa2+ sensitivity of smooth muscle and nonmuscle myosin II.β Physiol. Rev., 83, 1325β1358.
β’ Webb, R. C. (2003). βSmooth muscle contraction and relaxation.β Adv. Physiol. Educ., 27, 201β206.
β’ Hirano, K. (2007). βCurrent topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle.β J. Pharmacol. Sci., 104, 109β115.